Why India rejected a patent application for shorter drug-resistant TB treatment
The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
Attributed summary
The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
Read the original report — The Hindu Health
Storywire publishes attributed summaries for discoverability. Full reporting remains with the original publisher — we do not republish restricted full text.
Related stories
